PreTect HPV-Proofer 5®Clinically Relevant Answers in Cervical Cancer Prevention

  • Not all HPV genotypes carry the same risk. The goal is to find the ones that trigger cervical cancer and pre-empt it.
  • High specificity triage in ASC-US and grade 1 cervical intraepithelial neoplasia 1 (CIN 1) cytology diagnosis.
  • Identification of precursor lesions most likely to progress to invasive cancer.
  • Suitable for use even in young women.
  • Higher specificity than other tests, resulting in accurate patient management and avoiding unnecessary treatment.
  • Only for use by healthcare professionals.
  • Intrinsic sample control to check specimen quality and detect factors inhibiting amplification.

E6/E7 mRNAand the Link to Cervical Cancer

  • The main cause of cervical cancer is the presence of E6/E7 oncoproteins in HPV.
  • More than 80% of Cervical Cancer cases worldwide are caused by HPV genotypes 16, 18, 31, 33, and 45.1
  • The optimal detection strategy requires high specificity and accurate individual patient management to minimize unnecessary treatment due to false positives.

1 WHO. https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer

NASBA TECHNOLOGY:Nucleic Acid Sequence-Based Amplification

PreTect HPV-Proofer 5® is based on NASBA technology, an enzymatic amplification process that can amplify and detect RNA even in the presence of DNA. Unlike PCR, an amplification run is performed under isothermal conditions at 41°C, achieving a fast result.

Video Coming Soon

YOUR QUESTIONS ANSWEREDPreTect HPV-Proofer 5® FAQs

What is the difference between PreTect SEE® y PreTect-HPV Proofer 5®?

PreTect SEE® identifies three of the most important HR-HPV (16, 18, and 45) genotypes related to cervical cancer while PreTect HPV-Proofer 5® identifies five HR-HPV genotypes (16, 18, 31, 33, and 45).

What about the HR-HPV types not detected by PreTect HPV-Proofer 5®?

PreTect HPV-Proofer 5® detects five of the most common HR-HPV genotypes related to cervical cancer. These five HR-HPV types are related to >80 % of all cervical cancer cases in the world.

Is PreTect HPV-Proofer 5® clinically validated?

PreTect HPV-Proofer 5® is clinically validated according to the EU IVD regulations.

Molecular TechnologyOur Products

We develop medical devices and safe, state-of-the-art molecular technologies that empower you to take control of your health through prevention.

  • Mia Product Image with test tube

    Medical Devices

    User-friendly. Safe.

    The Mel-Mont Medical portfolio offers patented and versatile products for HR-HPV-related cancer prevention.

    View Products
  • photo of someone holding a medical device for in-vitro testing

    In Vitro Diagnosis

    Experience. Reliability.

    Our PreTect division offers molecular assays for nucleic acid amplification, along with an ISO 13485-certified HPV-mRNA molecular laboratory service.

    View Products
  • Two hands holding molecular consumables products

    Sample Prep Reagents

    Efficiency. Cost-effectiveness.

    Our sample preparation reagents portfolio includes sample preparations for molecular testing and a transport medium.

    View Products

Have Questions? Our team is happy to answer any questions you may have.

Contact Us